Clinical Trial Detail

NCT ID NCT03578367
Title Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

chronic myeloid leukemia

Therapies

Imatinib

Nilotinib

Asciminib + Imatinib

Age Groups: adult senior

No variant requirements are available.